81_FR_3834 81 FR 3820 - Notice Pursuant to the National Cooperative Research and Production Act of 1993-Consortium Management Group, Inc. on Behalf of Medical Countermeasure Systems Consortium

81 FR 3820 - Notice Pursuant to the National Cooperative Research and Production Act of 1993-Consortium Management Group, Inc. on Behalf of Medical Countermeasure Systems Consortium

DEPARTMENT OF JUSTICE
Antitrust Division

Federal Register Volume 81, Issue 14 (January 22, 2016)

Page Range3820-3820
FR Document2016-01265

Federal Register, Volume 81 Issue 14 (Friday, January 22, 2016) 
[Federal Register Volume 81, Number 14 (Friday, January 22, 2016)]
[Notices]
[Page 3820]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-01265]



[[Page 3820]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Consortium Management Group, Inc. on Behalf of 
Medical Countermeasure Systems Consortium

    Notice is hereby given that, on December 8, 2015, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Consortium Management 
Group, Inc. on behalf of Medical Countermeasure Systems Consortium 
(``CMG-MCSC'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing (1) the 
identities of the parties to the venture and (2) the nature and 
objectives of the venture. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the identities of the parties 
to the venture are: Consortium Management Group, Inc. on behalf of 
Medical Countermeasure Systems Consortium, Washington, DC; ABL, Inc., 
Rockville, MD; Altimmune, Inc., Gaithersburg, MD; AEQUOR, Inc., 
Oceanside, CA; Appili Therapeutics, Inc., Halifax, Nova Scotia; 
BalinBac Therapeutics, Inc., Princeton, NJ; Battelle, Columbus, OH; 
Bavarian Nordic, Kvistgard, DENMARK; Chemapotheca LLC, Delamar, NY; 
CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Creare LLC, Hanover, NH; 
CUBRC, Inc., Buffalo, NY; Dyne Immune Institute for Translational 
Medicine and Research, Wurtsboro, NY; DynPort Vaccine Company LLC, a 
CSC Company, Frederick, MD; Elusys Therapeutics, Inc., Pine Brook, NJ; 
Emergent Biosolutions Inc., Gaithersburg, MD; First Line Technology, 
LLC, Chantilly, VA; GenArraytion, Inc., Rockville, MD; Ginkgo Bioworks, 
Boston, MA; IIT Research Institute, Chicago, IL; Institute for 
Therapeutic Innovation, University of Florida, Orlando, FL; 
InvivoSciences, Inc. Madison, WI; Lovelace Biomedical and Environmental 
Research Institute (LBERI), Albuquerque, NM; Luminex Corporation, 
Austin, TX; Maurer & Hutson Consulting, Seattle, WA; MediVector, Inc., 
Boston, MA; Mesa Science Associates, Inc., Frederick, MD; Molecular 
Engineering & Sciences Institute, Seattle, WA; Murtech, Inc., Glen 
Burnie, MD; Nanotherapeutics, Inc., Alachua, FL; Noninvasix, Inc., 
Galveston, TX; Philips Healthcare, Andover, MA; PnuVax Incorporated, 
Kingston, CANADA; The Preclinical Radiobiology Laboratory, Division of 
Translational Radiation Sciences, Department of Radiation Oncology, 
University of Maryland, School of Medicine, Baltimore, MD; Quintiles, 
Inc., Durham, NC; Science Applications International Corporation, 
McLean, VA; Smart Consulting Group, West Chester, PA; Southern 
Research, Birmingham, AL; Southwest Research Institute, San Antonio, 
TX; Spero Therapeutics, Cambridge, MA; Therabron Therapeutics, Inc., 
Rockville, MD; Trideum Biosciences LLC, Huntsville, AL; University of 
Pittsburgh Center for Military Medicine Research, Pittsburgh, PA; 
Vaxess Technologies, Inc., Cambridge, MA; and Washington to Washington 
Consulting, Seattle, WA.
    The general area of the CMG-MCSC's planned activity is (a) to enter 
into an Other Transaction Agreement (``OTA'') with the U.S. Government 
(``Government'') for the funding of certain research, development, 
testing and evaluation of prototypes to be conducted as a collaboration 
between the Government and Consortium Members, to enhance the 
capabilities of the Government and its departments and agencies in the 
field of countermeasures against chemical, biological, radiological and 
nuclear threats; (b) to develop countermeasures, first response and 
resilient systems; (c) to participate in the establishment of sound 
technical and programmatic performance goals based on the needs and 
requirements of the Government's Technology Objectives; (d) to provide 
a unified voice to effectively articulate the global and strategically 
important role medical countermeasures play in current and future 
national security objectives; and (e) to maximize the utilization of 
the Government's and Members' capabilities to effectively develop 
critical technologies which can be deployed and transitioned.

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-01265 Filed 1-21-16; 8:45 am]
 BILLING CODE P

3820 Federal Register / Vol. 81, No. 14 / Friday, January 22, 2016 / Notices DEPARTMENT OF JUSTICE Galveston, TX; Philips Healthcare, DEPARTMENT OF JUSTICE Andover, MA; PnuVax Incorporated, Antitrust Division Kingston, CANADA; The Preclinical Antitrust Division Radiobiology Laboratory, Division of Notice Pursuant to the National Notice Pursuant to the National Translational Radiation Sciences, Cooperative Research and Production Cooperative Research and Production Department of Radiation Oncology, Act of 1993—Consortium Management Act of 1993—IMS Global Learning University of Maryland, School of Group, Inc. on Behalf of Medical Consortium, Inc. Countermeasure Systems Consortium Medicine, Baltimore, MD; Quintiles, Inc., Durham, NC; Science Applications Notice is hereby given that, on Notice is hereby given that, on International Corporation, McLean, VA; December 8, 2015, pursuant to Section December 29, 2015, pursuant to Section Smart Consulting Group, West Chester, 6(a) of the National Cooperative 6(a) of the National Cooperative PA; Southern Research, Birmingham, Research and Production Act of 1993, Research and Production Act of 1993, AL; Southwest Research Institute, San 15 U.S.C. 4301 et seq. (‘‘the Act’’), 15 U.S.C. 4301 et seq. (‘‘the Act’’), IMS Antonio, TX; Spero Therapeutics, Consortium Management Group, Inc. on Global Learning Consortium, Inc. (‘‘IMS Cambridge, MA; Therabron behalf of Medical Countermeasure Global’’) has filed written notifications Therapeutics, Inc., Rockville, MD; Systems Consortium (‘‘CMG–MCSC’’) simultaneously with the Attorney Trideum Biosciences LLC, Huntsville, has filed written notifications General and the Federal Trade AL; University of Pittsburgh Center for simultaneously with the Attorney Commission disclosing changes in its Military Medicine Research, Pittsburgh, General and the Federal Trade membership. The notifications were PA; Vaxess Technologies, Inc., Commission disclosing (1) the identities filed for the purpose of extending the of the parties to the venture and (2) the Cambridge, MA; and Washington to Act’s provisions limiting the recovery of nature and objectives of the venture. Washington Consulting, Seattle, WA. antitrust plaintiffs to actual damages The notifications were filed for the The general area of the CMG–MCSC’s under specified circumstances. purpose of invoking the Act’s provisions planned activity is (a) to enter into an Specifically, Cobb County School limiting the recovery of antitrust Other Transaction Agreement (‘‘OTA’’) District, Smyrna, GA; Duncanville ISD, plaintiffs to actual damages under with the U.S. Government Duncanville, TX; EdX Inc., Cambridge, specified circumstances. (‘‘Government’’) for the funding of MA; eSyncTraining, Irvine, CA; Pursuant to Section 6(b) of the Act, certain research, development, testing K12.com, Herndon, VA; Motivis the identities of the parties to the and evaluation of prototypes to be Learning, Salem, NH; Otus, Highland venture are: Consortium Management conducted as a collaboration between Park, IL; and Southern New Hampshire Group, Inc. on behalf of Medical the Government and Consortium Countermeasure Systems Consortium, University/College for America, Members, to enhance the capabilities of Manchester, NH, have been added as Washington, DC; ABL, Inc., Rockville, the Government and its departments MD; Altimmune, Inc., Gaithersburg, parties to this venture. and agencies in the field of MD; AEQUOR, Inc., Oceanside, CA; Also, Saylor Foundation, Washington, countermeasures against chemical, Appili Therapeutics, Inc., Halifax, Nova DC; and Blue Canary, Chandler, AZ, biological, radiological and nuclear Scotia; BalinBac Therapeutics, Inc., have withdrawn as parties to this threats; (b) to develop countermeasures, Princeton, NJ; Battelle, Columbus, OH; venture. Bavarian Nordic, Kvistgard, DENMARK; first response and resilient systems; (c) to participate in the establishment of No other changes have been made in Chemapotheca LLC, Delamar, NY; sound technical and programmatic either the membership or planned CONTINUUS Pharmaceuticals, Inc., performance goals based on the needs activity of the group research project. Woburn, MA; Creare LLC, Hanover, NH; and requirements of the Government’s Membership in this group research CUBRC, Inc., Buffalo, NY; Dyne Immune Institute for Translational Technology Objectives; (d) to provide a project remains open, and IMS Global Medicine and Research, Wurtsboro, NY; unified voice to effectively articulate the intends to file additional written DynPort Vaccine Company LLC, a CSC global and strategically important role notifications disclosing all changes in Company, Frederick, MD; Elusys medical countermeasures play in membership. Therapeutics, Inc., Pine Brook, NJ; current and future national security On April 7, 2000, IMS Global filed its Emergent Biosolutions Inc., objectives; and (e) to maximize the original notification pursuant to Section Gaithersburg, MD; First Line utilization of the Government’s and 6(a) of the Act. The Department of Technology, LLC, Chantilly, VA; Members’ capabilities to effectively Justice published a notice in the Federal GenArraytion, Inc., Rockville, MD; develop critical technologies which can Register pursuant to Section 6(b) of the Ginkgo Bioworks, Boston, MA; IIT be deployed and transitioned. Act on September 13, 2000 (65 FR Research Institute, Chicago, IL; Institute 55283). for Therapeutic Innovation, University Patricia A. Brink, of Florida, Orlando, FL; InvivoSciences, Director of Civil Enforcement, Antitrust The last notification was filed with Inc. Madison, WI; Lovelace Biomedical Division. the Department on October 13, 2015. A and Environmental Research Institute [FR Doc. 2016–01265 Filed 1–21–16; 8:45 am] notice was published in the Federal (LBERI), Albuquerque, NM; Luminex BILLING CODE P Register pursuant to Section 6(b) of the Act on November 10, 2015 (80 FR mstockstill on DSK4VPTVN1PROD with NOTICES Corporation, Austin, TX; Maurer & Hutson Consulting, Seattle, WA; 69698). MediVector, Inc., Boston, MA; Mesa Patricia A. Brink, Science Associates, Inc., Frederick, MD; Director of Civil Enforcement, Antitrust Molecular Engineering & Sciences Division. Institute, Seattle, WA; Murtech, Inc., [FR Doc. 2016–01251 Filed 1–21–16; 8:45 am] Glen Burnie, MD; Nanotherapeutics, Inc., Alachua, FL; Noninvasix, Inc., BILLING CODE P VerDate Sep<11>2014 16:59 Jan 21, 2016 Jkt 238001 PO 00000 Frm 00045 Fmt 4703 Sfmt 9990 E:\FR\FM\22JAN1.SGM 22JAN1


Document Created: 2016-01-22 01:16:57
Document Modified: 2016-01-22 01:16:57
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
FR Citation81 FR 3820 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR